Peptide LibraryCagriSema dosage in published studies and labels
These are the doses used for CagriSema in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
CagriSema has no approved dosage. It is a fixed combination of cagrilintide and semaglutide, and human dosing comes from Novo Nordisk's phase 3 trials, which gave 2.4 mg of each under the skin once a week: in REDEFINE 1, mean weight change at 68 weeks was -20.4% against -3.0% with placebo in adults without diabetes. A lower 1.0 mg + 1.0 mg combination was also tested in type 2 diabetes.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 1.0 mg or 2.4 mg of each component once weekly in phase 3 trials |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | 40–68 weeks in the published phase 3 trials |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| REDEFINE 1 — phase 3a, overweight or obesity (NCT05567796)Clinical trial · Randomized, double-blind, placebo- and active-controlled phase 3a trial | Adults with obesity, or overweight with a related condition, without diabetes (n=3,417) | Cagrilintide 2.4 mg + semaglutide 2.4 mg (compared with each alone and placebo) | Subcutaneous | Once weekly | 68 weeks | Mean body-weight change -20.4% with CagriSema against -3.0% with placebo; gastrointestinal events in 79.6% against 39.9% | Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. |
| REDEFINE 2 — phase 3a, obesity with type 2 diabetes (NCT05394519)Clinical trial · Randomized, double-blind, placebo-controlled phase 3a trial | Adults with BMI ≥27, HbA1c 7–10% and type 2 diabetes (n=1,206) | Cagrilintide 2.4 mg + semaglutide 2.4 mg | Subcutaneous | Once weekly | 68 weeks | Mean body-weight change -13.7% against -3.4% with placebo; HbA1c ≤6.5% reached by 73.5% against 15.9% | Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025. |
| REIMAGINE 1 — phase 3a, early type 2 diabetes (NCT06323174)Clinical trial · Randomized, double-blind, placebo-controlled phase 3a trial | Adults with type 2 diabetes on diet and exercise (n=189) | 2.4 mg + 2.4 mg, or 1.0 mg + 1.0 mg | Subcutaneous | Once weekly | 40 weeks | HbA1c change -1.8 points (2.4 mg each) and -1.5 points (1.0 mg each) against -0.1 with placebo; weight change -13.8% and -11.8% against -1.4% | Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1). Lancet Diabetes Endocrinol. 2026. |
| REIMAGINE 2 — phase 3, versus semaglutide or cagrilintide aloneClinical trial · Randomized, double-blind, placebo- and active-controlled phase 3 trial | Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor, BMI ≥25 (n=2,713) | 2.4 mg + 2.4 mg, or 1.0 mg + 1.0 mg (compared with semaglutide alone, cagrilintide alone and placebo) | Subcutaneous | Once weekly | 68 weeks | HbA1c change -1.91 points with CagriSema 2.4 mg each against -1.75 with semaglutide 2.4 mg alone (difference -0.16) | Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026. |
Where sources disagree
- CagriSema doses are given as the amount of each component: 2.4 mg + 2.4 mg means 2.4 mg of cagrilintide and 2.4 mg of semaglutide in the same weekly injection, 4.8 mg of peptide in total. The trials used a fixed-dose product, not two drugs measured separately.
- Semaglutide 2.4 mg weekly is also the Wegovy maintenance dose, but CagriSema is not approved, and its trial results do not belong to semaglutide or cagrilintide alone; see the semaglutide and cagrilintide profiles for each on its own.
- A vial labelled with one strength does not say how that amount is divided between the two compounds. The reconstitution figures below are for the labelled total only.